Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

The response to neoadjuvant chemotherapy in breast cancer patients is usually assessed by pCR and RCB score. However, the prognostic value of these parameters is still in discussion. We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Exner, Ruth, Sachet, Monika, Arnold, Tobias, Zinn‐Zinnenburg, Mercedes, Michlmayr, Anna, Dubsky, Peter, Bartsch, Rupert, Steger, Guenther, Gnant, Michael, Bergmann, Michael, Bachleitner‐Hofmann, Thomas, Oehler, Rudolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055166/
https://www.ncbi.nlm.nih.gov/pubmed/27457217
http://dx.doi.org/10.1002/cam4.827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055166/
https://www.ncbi.nlm.nih.gov/pubmed/27457217
http://dx.doi.org/10.1002/cam4.827

Ejemplares similares